... factor that will undoubtedly influence therapeutic efficacy. 1 To whom correspondence should be addressed (email [email protected] ). 31 3 2014 © The Authors Journal compilation © 2014 Biochemical Society 2014 acquired resistance Akt alternative reading frame...

... 2014 Biochemical Society 2014 acquired resistance breast cancer human epidermal growth factor receptor 2 (HER2) Numerous mechanisms of acquired resistance to HER2-directed therapy have been identified in pre-clinical studies. These frequently involve changes in HER2 expression...

... of certain cancers. Despite these advances, however, only a subset of patients respond to these agents in the first instance, and, of those that do, acquired resistance invariably develops after several months. Studies in vitro have identified various mechanisms that can underpin intrinsic and acquired...

... the role of signalling plasticity in the context of the mechanisms underlying both intrinsic and acquired resistance to targeted cancer therapies. We then examine the emerging analytical techniques and theoretical paradigms that are contributing to a greater understanding of signalling on a global...

... by Astex Therapeutics Ltd and Cancer Research UK. 2 To whom correspondence should be addressed (email [email protected] ). 5 2 2014 © The Authors Journal compilation © 2014 Biochemical Society 2014 acquired resistance murine double minute 2 inhibitor (MDM2 inhibitor...

... 792 10.1056/NEJMoa044238 15728811 28 Pao W. Miller V.A. Politi K.A. Riely G.J. Somwar R. Zakowski M.F. Kris M.G. Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain...

..., tumours are likely to adapt and acquire resistance to mTOR inhibitors. In the present article, we review studies that describe how tumour cells adapt to become resistant to mTOR inhibitors. mTOR is a central signalling hub which responds to an array of signalling inputs and activates a range of downstream...

... and MEK1/2 inhibitors are currently undergoing clinical evaluation, but their ultimate success is likely to be limited by acquired drug resistance. We have used colorectal cancer cell lines harbouring mutations in B-Raf or K-Ras to model acquired resistance to the MEK1/2 inhibitor selumetinib (AZD6244...